NASDAQ:TWST - Twist Bioscience Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $118.00
  • Forecasted Upside: 8.11 %
  • Number of Analysts: 6
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$109.15
▼ -2.96 (-2.64%)

This chart shows the closing price for TWST by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Twist Bioscience Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TWST and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TWST

Analyst Price Target is $118.00
▲ +8.11% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Twist Bioscience in the last 3 months. The average price target is $118.00, with a high forecast of $150.00 and a low forecast of $100.00. The average price target represents a 8.11% upside from the last price of $109.15.

This chart shows the closing price for TWST for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 6 investment analysts is to hold stock in Twist Bioscience. This rating has held steady since January 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/4/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/3/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/1/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/30/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
3/30/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
6/28/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
8/27/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
9/26/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/9/2021Robert W. BairdLower Price TargetOutperform$140.00 ➝ $130.00Low
6/29/2021William BlairInitiated CoverageOutperformHigh
6/4/2021The Goldman Sachs GroupInitiated CoverageNeutral$110.00Low
4/12/2021Piper SandlerInitiated CoverageOverweight$150.00Medium
2/5/2021Robert W. BairdBoost Price TargetOutperform$125.00 ➝ $200.00Medium
2/5/2021JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$100.00High
11/24/2020Robert W. BairdBoost Price TargetOutperform$70.00 ➝ $125.00High
11/24/2020SVB LeerinkBoost Price TargetMarket Perform$90.00 ➝ $100.00High
10/20/2020SVB LeerinkInitiated CoverageMarket PerformHigh
7/8/2020CowenReiterated RatingBuyMedium
2/7/2020Evercore ISIInitiated CoverageBuy$42.00Low
2/3/2020CowenReiterated RatingBuyHigh
5/31/2019Evercore ISIInitiated CoverageOutperform$26.66High
12/2/2018JPMorgan Chase & Co.Initiated CoverageNeutral$27.00 ➝ $25.99High
11/26/2018Robert W. BairdInitiated CoverageOutperformMedium
11/26/2018JPMorgan Chase & Co.Initiated CoverageNeutral ➝ Neutral$27.00Medium
11/26/2018CowenInitiated CoverageOutperformMedium
(Data available from 9/27/2016 forward)

News Sentiment Rating

0.51 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/1/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/31/2021
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/30/2021
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/30/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/29/2021
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/29/2021
  • 6 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/28/2021
  • 5 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
9/27/2021

Current Sentiment

  • 5 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Twist Bioscience logo
Twist Bioscience Corp. develops proprietary semiconductor-based synthetic DNA manufacturing process. It produces synthetic biology tools such as genes, oligo pools, variant libraries, DNA data storage and NGS. The firm also produces agriculture production as well as new applications such as in vivo diagnostics, biodetection and data storage. The company was founded by William Marine Banyai, Emily Marine Leproust and Bill James Peck in February 2013 and is headquartered in San Francisco, CA.
Read More

Today's Range

Now: $109.15
Low: $109.04
High: $111.57

50 Day Range

MA: $113.06
Low: $95.64
High: $124.12

52 Week Range

Now: $109.15
Low: $66.12
High: $214.07

Volume

964 shs

Average Volume

710,085 shs

Market Capitalization

$5.38 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.7

Frequently Asked Questions

What sell-side analysts currently cover shares of Twist Bioscience?

The following Wall Street analysts have issued reports on Twist Bioscience in the last year: JPMorgan Chase & Co., Piper Sandler, Robert W. Baird, SVB Leerink LLC, The Goldman Sachs Group, Inc., William Blair, and Zacks Investment Research.
View the latest analyst ratings for TWST.

What is the current price target for Twist Bioscience?

5 Wall Street analysts have set twelve-month price targets for Twist Bioscience in the last year. Their average twelve-month price target is $118.00, suggesting a possible upside of 5.3%. Piper Sandler has the highest price target set, predicting TWST will reach $150.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $100.00 for Twist Bioscience in the next year.
View the latest price targets for TWST.

What is the current consensus analyst rating for Twist Bioscience?

Twist Bioscience currently has 1 sell rating, 2 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in TWST, but not buy more shares or sell existing shares.
View the latest ratings for TWST.

What other companies compete with Twist Bioscience?

How do I contact Twist Bioscience's investor relations team?

Twist Bioscience's physical mailing address is 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is (800) 719-0671 and its investor relations email address is [email protected] The official website for Twist Bioscience is www.twistbioscience.com.